<DOC>
	<DOCNO>NCT02452112</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study design ass efficacy safety 5 % lidocaine patch , follow placebo active patch application placebo insensitive subject .</brief_summary>
	<brief_title>Efficacy Safety 5 % Lidocaine Patch With Placebo Patch Subjects With Herpes Zoster Associated Pain</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>1 . Male female subject 18 85 year age . 2 . Subjects must herpes zoster associate pain present ≥1 month heal acute herpes zoster skin rash locate face , scalp ; diagnosis base physical examination review available medical record confirm episode herpes zoster . 3 . Herpes zoster associate pain must least moderate severity , define average pain level ≥40 mm 100 mm visual analog scale ( VAS slide ruler ) 1 . Subjects sign cord brainstem injury herpes zoster . 2 . Presence another pain problem great severity herpes zoster associate pain . 3 . Subjects undergone neurolytic nerve block ablative neurosurgical procedure control herpes zoster associate pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>